Bentsu Ro

Array ( [id] => 17297861 [patent_doc_number] => 20210393700 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR ACTIVATION AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/765060 [patent_app_country] => US [patent_app_date] => 2018-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58101 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -231 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16765060 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19013023 [patent_doc_number] => 11919938 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-05 [patent_title] => Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors PD1 and PD-L1 [patent_app_type] => utility [patent_app_number] => 16/321385 [patent_app_country] => US [patent_app_date] => 2018-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 16940 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16321385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18964197 [patent_doc_number] => 11897948 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Treatment of chronic kidney disease and other renal dysfunction using a GDF15 modulator [patent_app_type] => utility [patent_app_number] => 16/179166 [patent_app_country] => US [patent_app_date] => 2018-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 9 [patent_no_of_words] => 12019 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 618 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16179166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14896975 [patent_doc_number] => 20190292253 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => METHODS OF REVERSING CACHEXIA AND PROLONGING SURVIVAL COMPRISING ADMINISTERING A GDF15 MODULATOR AND AN ANTI-CANCER AGENT [patent_app_type] => utility [patent_app_number] => 16/179352 [patent_app_country] => US [patent_app_date] => 2018-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10177 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16179352 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14896971 [patent_doc_number] => 20190292251 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => TREATMENT OF CONGESTIVE HEART FAILURE AND OTHER CARDIAC DYSFUNCTION USING A GDF15 MODULATOR [patent_app_type] => utility [patent_app_number] => 16/177792 [patent_app_country] => US [patent_app_date] => 2018-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13523 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16177792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14185295 [patent_doc_number] => 20190112352 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-18 [patent_title] => TGF- RECEPTOR II ISOFORM, FUSION PEPTIDE, METHODS OF TREATMENT AND METHODS IN VITRO [patent_app_type] => utility [patent_app_number] => 16/173426 [patent_app_country] => US [patent_app_date] => 2018-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10912 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16173426 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16421940 [patent_doc_number] => 20200347138 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => DENDRITIC CELLS-TARGETING VACCINE [patent_app_type] => utility [patent_app_number] => 16/757084 [patent_app_country] => US [patent_app_date] => 2018-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19060 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 269 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16757084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19058976 [patent_doc_number] => 11938169 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => GM-CSF for treating refractory non-tuberculous mycobacteria infections [patent_app_type] => utility [patent_app_number] => 16/755178 [patent_app_country] => US [patent_app_date] => 2018-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 9029 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16755178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16208016 [patent_doc_number] => 20200241006 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => METHODS FOR MONITORING VEDOLIZUMAB TREATMENT [patent_app_type] => utility [patent_app_number] => 16/755090 [patent_app_country] => US [patent_app_date] => 2018-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28486 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16755090 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17923928 [patent_doc_number] => 11467169 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-11 [patent_title] => Inflammatory biomarkers for predicting responsiveness to FGF-18 compound [patent_app_type] => utility [patent_app_number] => 16/650878 [patent_app_country] => US [patent_app_date] => 2018-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 11967 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 224 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16650878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18029950 [patent_doc_number] => 11513128 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-29 [patent_title] => Metabolic biomarkers for predicting responsiveness to FGF-18 compound [patent_app_type] => utility [patent_app_number] => 16/650881 [patent_app_country] => US [patent_app_date] => 2018-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 11026 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16650881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14102303 [patent_doc_number] => 20190092827 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => Trapped Chemokine Variants as Therapeutic Agents for Inflammation-Related Diseases Including Infections, Diabetes, and Cancer [patent_app_type] => utility [patent_app_number] => 16/142101 [patent_app_country] => US [patent_app_date] => 2018-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3055 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16142101 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13837409 [patent_doc_number] => 20190022189 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => USE OF SERELAXIN TO REDUCE GDF-15 [patent_app_type] => utility [patent_app_number] => 16/137770 [patent_app_country] => US [patent_app_date] => 2018-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8799 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16137770 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16756617 [patent_doc_number] => 10975154 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-13 [patent_title] => Binding proteins and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/129438 [patent_app_country] => US [patent_app_date] => 2018-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 98 [patent_figures_cnt] => 99 [patent_no_of_words] => 83133 [patent_no_of_claims] => 56 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16129438 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283765 [patent_doc_number] => 20200277367 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => ANTIBODY VARIANTS [patent_app_type] => utility [patent_app_number] => 16/648147 [patent_app_country] => US [patent_app_date] => 2018-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14194 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16648147 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13622159 [patent_doc_number] => 20180362631 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => Pan-ELR+ CXC CHEMOKINE ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/119648 [patent_app_country] => US [patent_app_date] => 2018-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8007 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16119648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16111625 [patent_doc_number] => 20200207835 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => SRCP1-BASED THERAPY FOR DISEASES ASSOCIATED WITH PROTEIN AGGREGATION [patent_app_type] => utility [patent_app_number] => 16/639727 [patent_app_country] => US [patent_app_date] => 2018-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24486 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -49 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639727 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13929095 [patent_doc_number] => 20190048063 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION [patent_app_type] => utility [patent_app_number] => 16/049600 [patent_app_country] => US [patent_app_date] => 2018-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22095 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16049600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16908085 [patent_doc_number] => 11040102 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-22 [patent_title] => High concentration antibody formulations [patent_app_type] => utility [patent_app_number] => 16/045928 [patent_app_country] => US [patent_app_date] => 2018-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15524 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16045928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13551909 [patent_doc_number] => 20180327502 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => BINDING MEMBERS OF INTERLEUKIN-4 RECEPTOR ALPHA (IL4-Ra) [patent_app_type] => utility [patent_app_number] => 16/037544 [patent_app_country] => US [patent_app_date] => 2018-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42027 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16037544 [rel_patent_id] =>[rel_patent_doc_number] =>)